Sector
PharmaceuticalsOpen
₹634Prev. Close
₹631.4Turnover(Lac.)
₹923.32Day's High
₹654.95Day's Low
₹630.252 Week's High
₹67552 Week's Low
₹239.8Book Value
₹112.59Face Value
₹2Mkt Cap (₹ Cr.)
5,259.55P/E
32.38EPS
19.57Divi. Yield
0.13Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 16.1 | 16.1 | 16.1 | 14.64 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 799.27 | 683.36 | 599.59 | 253.95 |
Net Worth | 815.37 | 699.46 | 615.69 | 268.59 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 |
---|---|
Revenue | 385.36 |
yoy growth (%) | |
Raw materials | -128.12 |
As % of sales | 33.24 |
Employee costs | -32.76 |
Y/e 31 Mar( In .Cr) | Mar-2021 |
---|---|
Profit before tax | 167.31 |
Depreciation | -6.76 |
Tax paid | -43.71 |
Working capital | |
Other operating items |
Y/e 31 Mar | Mar-2021 |
---|---|
Growth matrix (%) | |
Revenue growth | |
Op profit growth | |
EBIT growth | |
Net profit growth |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,808.9 | 157.42 | 4,33,991.71 | 863.29 | 0.75 | 5,123.67 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,901.75 | 94.22 | 1,56,497.71 | 430 | 0.51 | 2,063 | 507.93 |
Cipla Ltd CIPLA | 1,584.6 | 30.22 | 1,27,967.54 | 1,178.16 | 0.82 | 3,969.86 | 360.74 |
Mankind Pharma Ltd MANKIND | 2,731.2 | 58.45 | 1,09,574.17 | 513.49 | 0 | 2,403.26 | 240.2 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,200.55 | 66.17 | 1,08,245.22 | 460 | 0.88 | 2,376 | 222.38 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Satish Waman Wagh
Whole-time Director
Smita Satish Wagh
Whole-time Director
Soloni Satish Wagh
Whole-time Director
Shivani Satish Wagh
Whole-time Director
Balasahab Gulabrao Sawant
Independent Director
Kedar Shankar Karmarkar
Independent Director
Bhairav Manojbhai Chokshi
Independent Director
Dileep Kumar Jain
Independent Director
Dinesh N Modi
Independent Director
Neelam Yashpal Arora
Company Sec. & Compli. Officer
Shweta Shivdhari Singh
Whole-time Director
Manoj Deo Dorlikar
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Supriya Lifescience Ltd
Summary
Supriya Lifescience Limited was initially constituted on October 29, 1985, as a Partnership Firm under the name M/s Supriya Chemicals. The Partnership Firm was last re-constituted pursuant to a Partnership Deed dated November 30, 2007. Upon the conversion of M/s Supriya Chemicals the Partnership Firm into a Public Limited Company, the Company got incorporated as Supriya Lifescience Limited vide certified on March 26, 2008 by the Registrar of Companies, Mumbai. The Company commenced operations in April, 2008. It is engaged in manufacturing and export of active pharmaceutical ingredients (APIs). The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients,with a focus on research and development. The company have niche product offerings of 39 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and antiallergic. The company have consistently been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, contributing to 45-55% and 65-70%, respectively,of the API exports from India, between Fiscal 2017 and 2020.The company is among the largest exporters of Salbutamol Sulphate from India in Fiscal 2020 in terms of volume.The companys products are approved by various international regulatory authorities such as USFDA, EUGMP, EDQM, SFDA NMPA, ANVISA, KFDA, PMDA, TGA and Taiwan FDA. As of 31 March 2021, the company have filed 11 active DMFs with USFDA
Read More
The Supriya Lifescience Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹653.5 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Supriya Lifescience Ltd is ₹5259.55 Cr. as of 05 Nov ‘24
The PE and PB ratios of Supriya Lifescience Ltd is 32.38 and 5.63 as of 05 Nov ‘24
The 52-week high/low is the highest and lowest price at which a Supriya Lifescience Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Supriya Lifescience Ltd is ₹239.8 and ₹675 as of 05 Nov ‘24
Supriya Lifescience Ltd's CAGR for 5 Years at N/I%, 3 Years at 17.34%, 1 Year at 148.58%, 6 Month at 57.79%, 3 Month at 59.04% and 1 Month at 10.88%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice